{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T19:07:03Z","timestamp":1790363223118,"version":"4.1.0"},"reference-count":37,"publisher":"American Society for Microbiology","issue":"12","license":[{"start":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T00:00:00Z","timestamp":1702512000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T00:00:00Z","timestamp":1702512000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2023,12,14]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    <jats:italic>Achromobacter<\/jats:italic>\n                    spp. and\n                    <jats:italic>Burkholderia cepacia<\/jats:italic>\n                    complex (Bcc) are rare but diverse opportunistic pathogens associated with serious infections, which are often multidrug resistant. This study compared the\n                    <jats:italic>in vitro<\/jats:italic>\n                    antibacterial activity of the siderophore antibiotic cefiderocol against\n                    <jats:italic>Achromobacter<\/jats:italic>\n                    spp. and Bcc isolates with that of other approved antibacterial drugs, including ceftazidime-avibactam, ciprofloxacin, colistin, imipenem-relebactam, and meropenem-vaborbactam. Isolates were collected in the SIDERO multinational surveillance program. Among 334\n                    <jats:italic>Achromobacter<\/jats:italic>\n                    spp. isolates [76.6% from respiratory tract infections (RTIs)], cefiderocol had minimum inhibitory concentration (MIC)\n                    <jats:sub>50\/90<\/jats:sub>\n                    of 0.06\/0.5 \u00b5g\/mL overall and 0.5\/4 \u00b5g\/mL against 52 (15.6%) carbapenem-non-susceptible (Carb-NS) isolates. Eleven (3.3%)\n                    <jats:italic>Achromobacter<\/jats:italic>\n                    spp. isolates overall and 6 (11.5%) Carb-NS isolates were not susceptible to cefiderocol. Among 425 Bcc isolates (73.4% from RTIs), cefiderocol had MIC\n                    <jats:sub>50\/90<\/jats:sub>\n                    of \u22640.03\/0.5 \u00b5g\/mL overall and \u22640.03\/1 \u00b5g\/mL against 184 (43.3%) Carb-NS isolates. Twenty-two (5.2%) Bcc isolates overall and 13 (7.1%) Carb-NS isolates were not susceptible to cefiderocol. Cumulative MIC distributions showed cefiderocol to be the most active of the agents tested\n                    <jats:italic>in vitro<\/jats:italic>\n                    against both\n                    <jats:italic>Achromobacter<\/jats:italic>\n                    spp. and Bcc. In a neutropenic murine lung infection model and a humanized pharmacokinetic immunocompetent rat lung infection model, cefiderocol showed significant bactericidal activity against two meropenem-resistant\n                    <jats:italic>Achromobacter xylosoxidans<\/jats:italic>\n                    strains compared with untreated controls (\n                    <jats:italic>P<\/jats:italic>\n                    &lt; 0.05) and vehicle-treated controls (\n                    <jats:italic>P<\/jats:italic>\n                    &lt; 0.05), respectively. Meropenem, piperacillin-tazobactam, ceftazidime, and ciprofloxacin comparators showed no significant activity in these models. The results suggest that cefiderocol could be a possible treatment option for RTIs caused by\n                    <jats:italic>Achromobacter<\/jats:italic>\n                    spp. and Bcc.\n                  <\/jats:p>","DOI":"10.1128\/aac.00346-23","type":"journal-article","created":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T09:00:35Z","timestamp":1700125235000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":20,"title":["<i>In vitro<\/i>\n                    and\n                    <i>in vivo<\/i>\n                    activity of cefiderocol against\n                    <i>Achromobacter<\/i>\n                    spp. and\n                    <i>Burkholderia cepacia<\/i>\n                    complex, including carbapenem-non-susceptible isolates"],"prefix":"10.1128","volume":"67","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1949-5555","authenticated-orcid":true,"given":"Miki","family":"Takemura","sequence":"first","affiliation":[{"name":"Laboratory for Drug Discovery and Disease Research, Shionogi &amp; Co., Ltd., Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0327-8932","authenticated-orcid":true,"given":"Rio","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of Biofunctional Evaluation \u0399I, Shionogi TechnoAdvance Research &amp; Co., Ltd., Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merime","family":"Ota","sequence":"additional","affiliation":[{"name":"Department of Biofunctional Evaluation \u0399I, Shionogi TechnoAdvance Research &amp; Co., Ltd., Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuichiro","family":"Nakai","sequence":"additional","affiliation":[{"name":"Department of Biofunctional Evaluation \u0399I, Shionogi TechnoAdvance Research &amp; Co., Ltd., Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel F.","family":"Sahm","sequence":"additional","affiliation":[{"name":"International Health Management Associates, Schaumburg, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3339-2701","authenticated-orcid":true,"given":"Meredith A.","family":"Hackel","sequence":"additional","affiliation":[{"name":"International Health Management Associates, Schaumburg, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinori","family":"Yamano","sequence":"additional","affiliation":[{"name":"Laboratory for Drug Discovery and Disease Research, Shionogi &amp; Co., Ltd., Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2447"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.25552"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01025-20"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2022.02.032"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S301153"},{"key":"e_1_3_4_7_2","first-page":"268","article-title":"Achromobacter xylosoxidans bacteremia: clinical and microbiological features in a 10-year case series","volume":"31","author":"Barrag\u00e1n EP","year":"2018","unstructured":"Barrag\u00e1n EP, P\u00e9rez JS, Corbella L, Orellana MA, Fern\u00e1ndez-Ruiz M. 2018. Achromobacter xylosoxidans bacteremia: clinical and microbiological features in a 10-year case series. Rev Esp Quimioter 31:268\u2013273.","journal-title":"Rev Esp Quimioter"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms10071449"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00685-20"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.52586\/5054"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00920-21"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2016.07.003"},{"key":"e_1_3_4_13_2","first-page":"1919","article-title":"Investigation of genes associated with producing betalactamase among Burkholderia cepacia isolates","volume":"14","author":"Tuwaij NSS","year":"2020","unstructured":"Tuwaij NSS, Aziz ZS, Al-ghazaly NF. 2020. Investigation of genes associated with producing betalactamase among Burkholderia cepacia isolates. Eurasia J Biosci 14:1919\u20131924.","journal-title":"Eurasia J Biosci"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmii.2021.09.009"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01990-21"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms9122473"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab466.1260"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab466.1252"},{"key":"e_1_3_4_19_2","unstructured":"CLSI. 2022. M100 - Performance standards for antimicrobial susceptibility testing (ed. 32). CLSI. Available from: https:\/\/clsi.org\/standards\/products\/microbiology\/education\/using-m100-ed32\/"},{"key":"e_1_3_4_20_2","unstructured":"The European committee on antimicrobial susceptibility testing. 2022. Breakpoint tables for interpretation of MICs and zone diameters. Version 12.0. Available from: http:\/\/www.eucast.org\/clinical_breakpoints\/"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02031-18"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01436-20"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2019.04.005"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00171-23"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00234-23"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/msystems.01291-22"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2023.06.003"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1089\/mdr.2020.0602"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa1847"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-020-00385-4"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics11121686"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.24945"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1099\/acmi.0.000413"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00700-17"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.36.7.1577"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkab221"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlac047"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1089\/mdr.2022.0279"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.00346-23","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.00346-23","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T09:08:42Z","timestamp":1702544922000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/aac.00346-23"}},"subtitle":[],"editor":[{"given":"Anne-Catrin","family":"Uhlemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2023,12,14]]},"references-count":37,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12,14]]}},"alternative-id":["10.1128\/aac.00346-23"],"URL":"https:\/\/doi.org\/10.1128\/aac.00346-23","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,14]]},"assertion":[{"value":"2023-03-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-11","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-11-16","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00346-23"}}